Myriad Genetics Conference Call Summary Company Overview - **Company**: Myriad Genetics (NasdaqGS:MYGN) - **Date**: March 10, 2026 - **Speakers**: CEO Sam Raha, CFO Ben Wheeler Key Points Management Insights - CEO Sam Raha purchased 40,000 shares, indicating personal conviction in the company's future [5][6] - The company is at a pivotal moment, focusing on a new strategy to serve the broader cancer care continuum, building on strengths in hereditary cancer [11][16] - There is a strong level of trust from customers based on product quality and scientific backing [14] Financial Guidance - The company projects a revenue midpoint of $870 million for 2026, expecting mid-single-digit sequential growth each quarter [23][25] - Historical trends show that the second half of the year typically contributes a higher proportion of annual revenue [27] - Key growth drivers include the launch of updated hereditary cancer panels and a dedicated sales channel for unaffected individuals [28][29] Product Performance - GeneSight is expected to grow mid-single-digit percentages, recovering from previous challenges [30] - The company added 12 payers for GeneSight last year, contributing to stability and growth potential [36] - The hereditary cancer segment saw a 6% annual growth, with a 9% growth in Q4, indicating positive momentum [33] Challenges and Solutions - The company faced challenges with UnitedHealthcare's non-coverage impacting GeneSight, but has focused on other growth opportunities [50] - Myriad has implemented new processes to enhance execution excellence, addressing past operational issues [84][86] - The order management system issues from the previous year have been resolved, and the company is optimistic about returning to growth in the prenatal segment [75][78] Upcoming Initiatives - The FirstGene mother-only assay is set to launch in Q3 2026, offering unique advantages such as earlier testing at eight weeks gestational age [101][104] - The company is focusing on expanding its market share in prenatal testing while minimizing cannibalization of existing products [106] Market Dynamics - The hereditary cancer market is expected to grow due to increasing cancer diagnoses, presenting opportunities for Myriad [74] - The company is actively working on enhancing its sales force and marketing strategies to drive growth in both hereditary and prenatal segments [58][59] ASP Considerations - Average Selling Prices (ASP) are expected to remain stable in 2026, with a slight decline anticipated due to product mix shifts [60][65] - The company experienced a 3% decline in ASP in 2025, primarily due to changes in UnitedHealthcare's policies [62] Conclusion - Myriad Genetics is positioning itself for growth through strategic product launches, improved operational execution, and a focus on customer trust and satisfaction. The company is optimistic about achieving its financial guidance and expanding its market presence in the coming years.

Myriad Genetics FY Conference Summary Company Overview - **Company**: Myriad Genetics (NasdaqGS:MYGN) - **Date of Conference**: March 03, 2026 - **Key Speakers**: Sam Raha (President and CEO), Ben Wheeler (CFO) Core Industry Insights - **Industry Focus**: Cancer care continuum, hereditary cancer testing, mental health pharmacogenomics, prenatal health - **Market Size**: Hereditary cancer testing market is valued at approximately $7 billion, with growth opportunities in high single digits Key Points and Arguments Strategic Priorities and Performance - **CEO Transition**: Sam Raha has been in the CEO role since April 30, 2025, focusing on redefining Myriad's strategy and priorities [4] - **Positive Developments**: Increased energy and enthusiasm within the company, successful recruitment of new talent, and a disciplined approach to growth in cancer care and other high-growth applications [5][6] - **Challenges**: Encountered delays in the rollout of a new order management system for the prenatal business, impacting execution [7] Financial Performance - **2025 Challenges**: Faced headwinds from UnitedHealthcare's policy changes affecting mental health pharmacogenomics, resulting in a revenue loss of over $40 million [10] - **2026 Guidance**: Projected revenue growth of 6% for 2026, with total revenue expected to be between $860 million and $880 million [9][15] - **Volume Growth**: GeneSight volume grew by 9% in Q4, indicating recovery and stabilization after a challenging year [11] Product Development and Launches - **New Product Focus**: Plans to launch more products in the next 18 months than in the previous five years, particularly in the cancer care continuum [7][8] - **Hereditary Cancer Testing**: Anticipated growth in hereditary cancer testing volume in 2026, with a focus on the MyRisk panel, which saw a 13% growth in Q4 [30] - **MRD Technology**: Introduction of the Precise MRD assay, an ultrasensitive test aimed at low-shedding cancers, with a focus on community oncology [34][35] Competitive Differentiation - **FirstGene Launch**: A combined carrier and prenatal screening test set to launch in the second half of 2026, designed for convenience and efficiency [54][55] - **AI-Enhanced Prolaris Test**: Scheduled for launch in Q2 2026, combining molecular and AI capabilities to improve decision-making in prostate cancer treatment [44][46] Market Dynamics and Regulatory Environment - **Biomarker Legislation**: Over 20 states have enacted biomarker laws, providing opportunities for Myriad's tests, particularly in cancer MRD and GeneSight [62][63] - **Payer Landscape**: Successfully added 12 payers for GeneSight coverage in 2025, with expectations for continued growth in 2026 [52] Financial Outlook and Profitability - **Adjusted EBITDA Guidance**: Expected adjusted EBITDA for 2026 is between $37 million and $49 million, with a focus on achieving free cash flow positivity [67][68] - **Capital Expenditure**: Anticipated CapEx of $20 million to $30 million annually for software and hard CapEx [68] M&A and Strategic Partnerships - **Focus on Partnerships**: Emphasis on strategic partnerships rather than M&A to enhance growth opportunities in the cancer care continuum [69] Conclusion and Investor Sentiment - **Growth Potential**: Myriad Genetics is positioned for high single-digit to low double-digit growth while maintaining profitability, with a strong focus on execution and accountability [70][72] - **Market Positioning**: The company aims to transition from a participant to a market-defining entity in the cancer care space [71]

Core Insights - Myriad Genetics reported fourth quarter revenue of approximately $210 million, exceeding the high end of its pre-announced range, with overall test volumes increasing by 2% year-over-year and underlying revenue growth of 4% after adjusting for an $8.1 million headwind from UnitedHealthcare's GeneSight coverage policy [3][7][2] Financial Performance - The company achieved consolidated revenue of $209.8 million, consistent with the previous year, and delivered 382,000 test results in the quarter [3][7] - Adjusted EBITDA for the quarter was reported at $14.3 million, with adjusted operating cash flow of $17.9 million and adjusted EPS of $0.04 [13] - Fourth quarter gross margin was 70%, down approximately 190 basis points year-over-year, attributed to the GeneSight revenue headwind [12] Segment Performance - In oncology, revenue reached $84.7 million, reflecting a 2% increase year-over-year, with MyRisk showing 14% volume growth in the affected market and 11% in the unaffected market [8][9] - Prolaris revenue growth accelerated to 16% year-over-year, driven by 12% volume growth, with investments in commercial channels to regain market share [9] - Women's health revenue was reported at $88.5 million, up 2% year-over-year, with hereditary cancer testing showing 3% revenue growth and 11% volume growth [9] Product Launches and Future Guidance - The company reaffirmed its full-year 2026 guidance of $860–880 million in revenue, with an adjusted gross margin of 68–69% and adjusted EBITDA of $37–49 million [5][14] - Myriad plans to launch an AI-enhanced Prolaris test in Q2 2026 and a full commercial launch of FirstGene prenatal screening in H2 2026 [6][15] - Management is reorganizing reporting into three strategic areas: cancer care continuum, prenatal health, and mental health, with a dedicated prenatal sales team [5][16] Operational Updates - Prenatal testing volumes declined year-over-year due to disruptions from a new test ordering system, but management is in an "active rebuild phase" to reactivate accounts and expand access [10] - GeneSight revenue for the fourth quarter was $36.6 million, supported by 9% year-over-year volume growth, with an expanded provider base of over 38,000 clinicians [11]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $210 million, exceeding the high end of the pre-announced range, with a year-over-year growth of approximately 4% when excluding the impact from UnitedHealthcare's decision on GeneSight [6][25] - For the full year 2025, revenue was $824.5 million, with adjusted EBITDA of $14.3 million and adjusted EPS of $0.04, reflecting strong operational performance [8][28] - Adjusted gross margin for the fourth quarter was 70%, with adjusted operating expenses decreasing by $7 million year-over-year due to disciplined cost management [8][27] Business Line Data and Key Metrics Changes - Oncology revenue for the fourth quarter was $84.7 million, growing 2% year-over-year, with MyRisk test volume growth of 14% in the affected market and 11% in the unaffected market [16][18] - Prolaris revenue growth accelerated to 16% year-over-year in the fourth quarter, driven by 12% volume growth [16][17] - Women's health revenue was $88.5 million, an increase of 2% year-over-year, with hereditary cancer testing in the unaffected market growing by 3% and volume growth of 11% [18][19] - GeneSight revenue was $36.6 million, with volume growth of 9% year-over-year, despite challenges from UnitedHealthcare's coverage policy change [22][24] Market Data and Key Metrics Changes - The company served over 55,000 healthcare providers and delivered over 1.5 million test reports in 2025, indicating strong market penetration [8] - The mental health business saw a record number of ordering clinicians, exceeding 38,000 in the fourth quarter [22] Company Strategy and Development Direction - The company is focusing on high-growth market segments and plans multiple product launches, including the expanded MyRisk panel and the AI-enhanced Prolaris test [5][10] - The strategy includes strengthening commercial capabilities and expanding the sales team, with an investment of over $35 million to enhance organizational efficiency and growth [15][61] - The company aims to maintain leadership in urinary cancer testing while expanding into other cancer testing applications [9][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high single-digit to low double-digit growth rates in 2027 and beyond, supported by new product launches and recovery in the prenatal business [39][40] - The company is optimistic about the potential for continued momentum in hereditary cancer testing and prenatal testing, with expectations for recovery in 2026 [20][21] Other Important Information - The company plans to simplify its reporting structure to align with its strategic focus areas, including cancer care continuum, prenatal health, and mental health [31][32] - The company is preparing for the commercial launch of Precise MRD for breast cancer, with an alpha launch starting next week [11][14] Q&A Session Summary Question: Confidence in long-term growth rate - Management highlighted the drivers of growth for 2026, including product launches and improvements in commercial execution, expressing confidence in returning to high single-digit growth rates [37][39] Question: MRD launch strategy - Management indicated a selective approach for the MRD launch, focusing on user experience and operational efficiency before expanding volume [40][42] Question: Prenatal growth expectations - Management acknowledged a decline in prenatal volume in Q1 but anticipated recovery in Q2 and beyond, supported by a focused sales team and new product launches [45][81] Question: Prolaris momentum and dynamics - Management noted that improved engagement with KOLs and expansion of the sales team contributed to Prolaris growth, while also acknowledging potential favorable comparisons in Q4 [74][76] Question: Customer impact from order management issues - Management emphasized the importance of addressing order management issues and expressed confidence in restoring customer relationships and achieving growth moving forward [86][88]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $210 million, exceeding the high end of the pre-announced range, with a year-over-year growth of approximately 4% when excluding the impact from UnitedHealthcare's decision on GeneSight [6][25] - For the full year 2025, revenue was $824.5 million, with adjusted EBITDA of $14.3 million and adjusted EPS of $0.04, reflecting disciplined cost management and strategic investments [8][28] - The adjusted gross margin for the fourth quarter was 70%, down approximately 190 basis points year-over-year due to the revenue headwind from GeneSight [9][26] Business Line Data and Key Metrics Changes - Oncology revenue for the fourth quarter was $84.7 million, with MyRisk test volume growth of 14% in the affected market and 11% in the unaffected market [16][18] - Prolaris revenue growth accelerated to 16% year-over-year in the fourth quarter, driven by a 12% increase in test volume [16][17] - Women's health revenue was $88.5 million, reflecting a 2% increase year-over-year, with hereditary cancer testing in the unaffected market growing by 3% and volume growth of 11% [18][19] Market Data and Key Metrics Changes - GeneSight volume grew 9% year-over-year, with a record number of ordering clinicians reaching over 38,000 [22] - The company faced challenges in prenatal testing, with a decline in volume due to order management disruptions, but expects recovery in 2026 [21][22] - The mental health segment showed resilience, with GeneSight revenues impacted by UnitedHealthcare's coverage policy change but still achieving positive coverage policies across 12 payers [23] Company Strategy and Development Direction - The company is focusing on high-growth market segments and plans multiple product launches, including the expanded MyRisk panel and the AI-enhanced Prolaris test [5][10] - A significant investment of over $35 million is planned to enhance organizational efficiency and commercial capabilities, particularly in the cancer care continuum [15][60] - The company aims to strengthen its position across cancer care testing while leveraging operational strengths for sample processing and reporting [33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high single-digit to low double-digit growth rates in 2027 and beyond, driven by new product launches and recovery in the prenatal business [39] - The company is optimistic about the potential for continued momentum in hereditary cancer testing and expects to regain share in the prenatal market [20][21] - Management emphasized the importance of execution excellence and rigorous testing before launching new products to avoid past issues [82] Other Important Information - The company plans to simplify its reporting structure to align with its refreshed strategy, focusing on cancer care continuum, prenatal health, and mental health as distinct categories [31] - The company maintains a solid balance sheet with access to $225 million in capital and intends to file a universal shelf registration [28] Q&A Session Summary Question: Confidence in long-term growth rate - Management highlighted several growth drivers for 2026, including product launches and improvements in commercial execution, expressing confidence in returning to high single-digit growth rates [38] Question: MRD launch strategy - Management indicated a selective approach for the MRD launch, focusing on user experience and operational efficiency before expanding volume [42] Question: Prenatal growth expectations - Management acknowledged a decline in prenatal volume in Q1 but expects recovery in Q2 and beyond, supported by a focused sales team and new product launches [44][76] Question: Prolaris momentum - Management noted that various initiatives, including engagement with KOLs and sales team expansion, contributed to Prolaris' growth, while also acknowledging potential favorable comparisons in Q4 [71][73]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $210 million, exceeding the high end of the pre-announced range, with a year-over-year growth of approximately 4% when excluding the impact from UnitedHealthcare's decision on GeneSight [4][24] - For the full year 2025, total revenue was $824.5 million, with over 1.5 million test reports delivered [6] - Adjusted gross margin for the fourth quarter was 70%, with adjusted EBITDA of $14.3 million and adjusted EPS of $0.04 [7][26] Business Line Data and Key Metrics Changes - Oncology revenue for the fourth quarter was $84.7 million, reflecting a 2% growth year-over-year, with MyRisk test volume growing 14% in the affected market and 11% in the unaffected market [16][18] - Prolaris revenue growth accelerated to 16% year-over-year in the fourth quarter, driven by a 12% increase in test volume [16][17] - Women's health revenue was $88.5 million, a 2% increase year-over-year, with hereditary cancer testing in the unaffected market growing by 3% and volume growth of 11% [18][19] - GeneSight generated revenues of $36.6 million with a 9% year-over-year volume growth [21] Market Data and Key Metrics Changes - The company served over 55,000 healthcare providers, with GeneSight achieving a record number of ordering clinicians exceeding 38,000 [6][21] - The prenatal testing segment experienced a decline in volume due to previous order management disruptions, but recovery is expected in 2026 [20][22] Company Strategy and Development Direction - The company is focusing on high-growth market segments and plans multiple product launches, including the expanded MyRisk panel and AI-enhanced Prolaris test [4][9] - A significant investment of over $35 million is planned to enhance organizational efficiency and commercial capabilities, particularly in cancer care [15][30] - The company aims to strengthen its position across cancer care testing while expanding its commercial capabilities and customer reach [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high single-digit to low double-digit growth rates in 2027 and beyond, driven by new product launches and recovery in the prenatal business [39] - The company is optimistic about the ongoing demand for its products and the positive momentum in hereditary cancer testing and GeneSight volumes [23][24] Other Important Information - The company plans to simplify its reporting structure to align with its refreshed strategy, focusing on cancer care continuum, prenatal health, and mental health as distinct categories [30] - The company is preparing for the commercial launch of Precise MRD for breast cancer, with an alpha launch starting next week [12][17] Q&A Session Summary Question: Confidence in long-term growth rate - Management highlighted the drivers of growth for 2026, including product launches and improvements in commercial execution, expressing confidence in returning to high single-digit growth rates [38][39] Question: MRD launch strategy - The company plans to be selective during the alpha phase of the MRD launch, focusing on user experience and operational efficiency before scaling up [41][42] Question: Prenatal growth expectations - Management acknowledged a decline in prenatal volume in Q1 but expects recovery in Q2 and beyond, supported by a focused sales team [44][78] Question: Prolaris momentum and dynamics - Management noted that various initiatives contributed to Prolaris growth, including engagement with key opinion leaders and expansion of the sales team [72][75] Question: GeneSight ASP trends - Management indicated that the trend in average selling price (ASP) for GeneSight is expected to improve as the company engages with payers and secures positive coverage policies [88]

Myriad Genetics FY Conference Summary Company Overview - **Company**: Myriad Genetics (NasdaqGS:MYGN) - **Industry**: Precision medicine and diagnostic testing - **Key Leadership**: Sam Raha (President and CEO), Ben Wheeler (CFO) [1][2] Core Points and Arguments Company Mission and Market Position - Myriad Genetics has a noble purpose to advance health and well-being, being a leader in precision medicine for over 30 years [2] - The company served over 55,000 healthcare providers and delivered over 1.5 million test reports in 2025 [3] Strategic Focus - The company is at an inflection point, focusing on the cancer care continuum and expanding its product portfolio beyond hereditary cancer [3][5] - Emphasis on execution excellence, utilizing AI across operations, product development, and customer experience [4][5] Market Opportunities - The total market opportunity for Myriad is estimated at $40 billion, with many served markets growing in double digits and having less than 50% market penetration [6] - Hereditary cancer testing represents a $7 billion market, with Myriad's myRisk test being the gold standard [9][10] Product Development and Launches - Upcoming launches include disease-specific panels for hereditary cancer and an AI-enabled Prolaris test for prostate cancer [10][13] - The company plans to expand its offerings in minimal residual disease (MRD) testing, starting with breast cancer, which has a $7 billion total addressable market (TAM) [19] Financial Performance and Projections - Projected revenue for 2025 is between $822 million and $824 million, with a 6% growth expected for 2026, targeting $860 million to $880 million [28][31] - The company aims to maintain industry-leading gross margins of 68%-69% while reducing costs [31][32] Growth Catalysts - Key growth drivers include the performance of hereditary cancer products, timely launches of new products, and consistent execution of financial and operational goals [38][40] - The company is investing over $35 million to strengthen commercial capabilities related to the cancer care continuum [30][52] Additional Important Content Partnerships and Collaborations - Myriad is exploring strategic partnerships to enhance its market position and product offerings, particularly in the cancer care continuum [45] - Collaborations with Sophia Genetics and MSK are aimed at biomarker selection and companion diagnostic development [12][45] Challenges and Market Dynamics - The prenatal health segment faced a 4% decline in 2025 due to implementation challenges, but recovery efforts are underway [29][30] - Mental health remains a growing area, with the GeneSight test being a market leader, having provided results for over three million patients [26][27] Long-term Vision - Myriad Genetics aims for high-single-digit to low-double-digit revenue growth over the next five years, supported by a robust pipeline of new products and strategic initiatives [33][36] This summary encapsulates the key insights from the Myriad Genetics FY Conference, highlighting the company's strategic direction, market opportunities, financial outlook, and growth initiatives.

Financial Performance and Guidance - Preliminary Q4 2025 total revenue is expected to be between $207 million and $209 million, and full year 2025 revenue between $822 million and $824 million[51] - Total test volume growth for 2025 is approximately 1% year-over-year, with Hereditary Cancer showing 7% growth, Mental Health 6% growth, and Prenatal Health a (4)% decrease[51] - 2026 total revenue guidance is set at $860 million to $880 million, reflecting approximately 6% growth compared to the midpoint of the preliminary 2025 revenue range[53] - Adjusted gross margin for 2026 is projected to be between 68% and 69%[53] - Adjusted EBITDA for 2026 is expected to be between $37 million and $49 million, representing approximately 43% growth over the midpoint of the previous full year 2025 guidance range[53] - The company is targeting high single-digit to low double-digit percentage annual revenue growth in the long term[60] Strategic Focus and Market Expansion - The company is prioritizing the Cancer Care Continuum to drive accelerated growth and profitability[11, 60] - The company plans to leverage market-leading positions and new products to accelerate growth in markets such as Hereditary Cancer Testing (HCT), therapy selection, prostate cancer, and molecular residual disease (MRD)[13] - The total addressable market (TAM) for therapy selection, HRD (Homologous Recombination Deficiency) & CGP (Comprehensive Genomic Profiling) is estimated at $8 billion, with an estimated annual market growth of 14-17%[13] - The MRD market has a TAM of $21 billion with an estimated annual market growth of 15-20%[13] - The company is expanding its testing menu to serve more of the Cancer Care Continuum, including hereditary cancer screening, diagnosis & therapy selection, and molecular residual disease monitoring[15, 16]

Myriad Genetics FY Conference Summary Company Overview - **Company**: Myriad Genetics (NasdaqGS:MYGN) - **Date of Conference**: December 02, 2025 Key Industry Insights - **Hereditary Cancer Market**: The unaffected population represents a $5 billion market opportunity, with significant growth potential as it remains less than a third penetrated [2][21] - **Mental Health Market**: Myriad Genetics is a market leader in mental health testing, with plans to maintain growth despite challenges from competitors [16][19] Core Company Strategies - **Focus on Cancer Care**: The updated strategy emphasizes a concentrated effort on the cancer care continuum, while managing growth in prenatal and mental health segments [3][8] - **Product Development**: Introduction of new products such as FirstGene and Early Access for prenatal screening, and an updated MyRisk product with 63 genes [7][10] - **Execution Excellence**: Acknowledgment of the need for improved execution in product development and market launch processes [3][4] Financial Performance - **Growth Metrics**: Mid-single-digit growth observed in GeneSight tests, with a return to growth in hereditary cancer testing after previous challenges [6][21] - **Revenue Projections**: GeneSight expected to generate over $150 million in revenue, with potential for mid-single to low double-digit growth rates [16][17] Competitive Landscape - **Market Positioning**: Myriad Genetics aims to differentiate itself from competitors like Natera and BillionToOne by leveraging its comprehensive product offerings and customer support [8][9] - **Guideline Engagement**: Active collaboration with Key Opinion Leaders (KOLs) to clarify NCCN guidelines and enhance the adoption of Myriad's Prolaris test for prostate cancer [12][13] Product Pipeline and R&D Focus - **MRD Testing**: Introduction of the Precise MRD assay, expected to launch in the first half of 2026, with a focus on low-shedding cancers [25][26] - **Partnerships**: Collaborations with Pathomic to accelerate R&D and market entry for new tests [29][33] - **Clinical Studies**: Over 20 studies in MRD across various cancer indications, with results expected to enhance clinical utility and guideline positioning [28][30] Challenges and Opportunities - **Reimbursement Issues**: Navigating reimbursement challenges, particularly with UnitedHealth's policy, while expanding payer coverage [16][20] - **Market Activation**: Efforts to activate the unaffected hereditary cancer market through improved workflows and sales strategies [22][23] Conclusion - Myriad Genetics is strategically positioning itself for growth in the hereditary cancer and mental health markets, with a strong focus on execution excellence and product innovation. The company is optimistic about its future prospects, particularly with the anticipated launch of new products and ongoing collaborations.

Core Insights - Myriad Genetics reported third-quarter revenue of $205.7 million, slightly above analyst estimates of $204.8 million, but experienced a 3.6% year-on-year decline [6] - Adjusted EPS was $0, beating analyst expectations of -$0.01, while adjusted EBITDA reached $10.3 million, significantly exceeding estimates of $5.57 million [6] - The company reaffirmed its full-year revenue guidance at $823 million and EBITDA guidance at $30 million, above analyst estimates of $27.52 million [6] Revenue and Profitability - The average revenue per test faced ongoing challenges, impacting overall market sentiment negatively despite meeting revenue expectations [1] - Operating margin decreased to -11.3%, down from -9.4% in the same quarter last year, indicating operational headwinds [6] Segment Performance - Strong volume growth was noted in the oncology segment, particularly for the MyRisk hereditary cancer test, which management views as a positive development [1] - The company faced pressures from reduced coverage for the GeneSight mental health test and a divested European business, but core test volumes showed signs of stabilization [1] Analyst Insights - Analysts raised questions regarding the balance between commercial investment and profitability, with management emphasizing an organizational redesign to support growth in cancer care while focusing on profit improvement [6] - Concerns were raised about the prenatal market share and operational improvements, with management addressing customer losses and future growth expectations from FirstGene [6] - Questions regarding hereditary cancer testing volume growth were clarified as stemming from improved customer workflows and EMR integration rather than a temporary rebound [6] Pricing and Market Dynamics - Average selling price declines in hereditary cancer tests were attributed to payer mix, biopharma revenue lumpiness, and changes in UnitedHealthcare's policy [6] - Plans to track an expanded provider base and multi-product adoption were highlighted as future key performance indicators [6] Operational Efficiency - Competitive turnaround times for Prequel and FirstGene tests were confirmed, with expectations for FirstGene to align with Prequel at launch [6]